Actinium Pharmaceuticals, Inc.
Symbool: ATNM
AMEX
8.75
USDMarktprijs vandaag
-5.3791
Koers/Winst Verhouding
0.0000
Koers/Winst Groei Verhouding
260.61M
MRK Kapitalisatie
- 0.00%
DIV Rendement
Actinium Pharmaceuticals, Inc. (ATNM) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 334.99 | 76.7 | 108.9 | 77.8 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 9.78 | 1.6 | 2 | 1.9 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 344.77 | 78.3 | 110.9 | 79.7 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 11.78 | 2.9 | 2.9 | 0.6 | ||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.long-term-investments | 1.25 | 0.3 | 0.3 | 0 | ||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | -0.6 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 13.02 | 3.2 | 3.3 | 0.6 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 357.79 | 81.4 | 114.2 | 80.4 | ||||||||||||||||||
balance-sheet.row.account-payables | 32.25 | 8 | 10.1 | 5.5 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 2.13 | 0.5 | 0.5 | 0.3 | ||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 6.51 | 1.6 | 2.1 | 0 | ||||||||||||||||||
Deferred Revenue Non Current | 140 | 35 | 35 | 0 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -106.57 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | -104.46 | -35 | -35 | 0 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 146.51 | 36.6 | 37.1 | 0 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 7.55 | 1.6 | 2.6 | 0.3 | ||||||||||||||||||
balance-sheet.row.total-liab | 180.9 | 45.1 | 47.7 | 6.8 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 0.11 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.retained-earnings | -1327.08 | -337.6 | -288.8 | -255.7 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1503.86 | 373.9 | 355.2 | 329.3 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 176.9 | 36.4 | 66.5 | 73.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 357.79 | 81.4 | 114.2 | 80.4 | ||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-equity | 176.9 | 36.4 | 66.5 | 73.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 357.79 | - | - | - | ||||||||||||||||||
Total Investments | 1.25 | 0.3 | 0.3 | 0 | ||||||||||||||||||
balance-sheet.row.total-debt | 8.64 | 2.1 | 2.6 | 0.3 | ||||||||||||||||||
balance-sheet.row.net-debt | -326.35 | -74.6 | -106.3 | -77.5 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -46.45 | -48.8 | -33 | -24.8 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.82 | 0.8 | 0.7 | 0.5 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | -3.47 | 2.2 | 0.4 | -1.5 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 4.23 | 3.8 | 2.8 | 1.7 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 1.77 | -3.1 | 38.2 | 1.7 | ||||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.account-payables | 0.15 | -2.2 | 4.6 | 1.2 | ||||||||||||||||||
cash-flows.row.other-working-capital | 1.61 | -1 | 33.6 | 0.5 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 5.72 | -2.2 | -0.4 | 1.5 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -39.63 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.09 | -0.2 | -0.4 | -0.1 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -0.09 | -0.2 | -0.4 | -0.1 | ||||||||||||||||||
cash-flows.row.debt-repayment | -0.01 | 0 | 0 | -0.1 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 28.61 | 14.9 | 23.2 | 35.3 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 19.08 | 0.3 | 23.1 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 28.87 | 14.9 | 23.1 | 35.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | -10.86 | -32.6 | 31.4 | 14.2 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 335.61 | 76.7 | 109.6 | 78.2 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 346.46 | 109.3 | 78.2 | 64 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | -39.63 | -47.3 | 8.6 | -20.9 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -0.09 | -0.2 | -0.4 | -0.1 | ||||||||||||||||||
cash-flows.row.free-cash-flow | -39.72 | -47.5 | 8.3 | -21 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0.08 | 0.1 | 1 | 1.1 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0.82 | 0.8 | 0.7 | 0.5 | ||||||||||||||||||
income-statement-row.row.gross-profit | -0.74 | -0.7 | 0.3 | 0.6 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 37.04 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 12.56 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.22 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 49.6 | 51.2 | 35.1 | 26.1 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 50.01 | 52 | 35.1 | 26.1 | ||||||||||||||||||
income-statement-row.row.interest-income | 3.48 | 3.1 | 1.1 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.55 | 0 | -1.1 | 0 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.22 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 3.48 | 3.1 | 1.1 | 0.2 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 3.48 | 3.1 | 1.1 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.55 | 0 | -1.1 | 0 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0.82 | 0.8 | 0.7 | 0.5 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | -49.11 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | -49.93 | -51.9 | -34.1 | -25 | ||||||||||||||||||
income-statement-row.row.income-before-tax | -46.45 | -48.8 | -33 | -24.8 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 0.55 | 0 | -1.1 | -0.2 | ||||||||||||||||||
income-statement-row.row.net-income | -46.45 | -48.8 | -31.9 | -24.6 |
Vaak gestelde vragen
Wat is Actinium Pharmaceuticals, Inc. (ATNM) totale activa?
Actinium Pharmaceuticals, Inc. (ATNM) totale activa is 81445000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 81000.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is -9.173.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -573.469.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -616.457.
Wat is Actinium Pharmaceuticals, Inc. (ATNM) nettowinst (netto-inkomen)?
De nettowinst is -48818000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 2113000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 51211000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 84057000.000.